– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint – – Safety...
All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months...
EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop...
Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which...
SAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company...
ALACHUA and TAMPA, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and...
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human studyTORONTO, Ontario and CAMBRIDGE,...
Positive data from the ROSALIE Phase 1/2 trial presented at 2023 SNO Annual Meeting Median survival of 14.5 months and...
HONG KONG, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven...
AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with...
Press release, Helsinki, 20 November 2023 at 11 AM (EET) Nexstim Receives NBS System 6 Order from Hospital in United...
Press Release, November 20, 2023 Connect, Collaborate, Innovate: the PSCC Unveils 'PSCC Connect', the Association of Economic Stakeholders in Oncology...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair...
November 20, 2023 Please see attachment. Contact information Investor RelationsAnders Mohr Christensen+45 2515 2364dkamc@chr-hansen.com Press RelationsSanne Seyer-Hansen+45 6038 6207dksash@chr-hansen.com Attachment...
Read the full announcement in PDF Attachment Update on merger EC offered remedy proposal
Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2-...
Allschwil, Switzerland, November 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs...
Regulated information – Inside information Despite Prior Positive Data, THR-149 Did Not Demonstrate Improvement in Vision Oxurion’s Board has...
LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
KELOWNA, BC / ACCESSWIRE / November 20, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology...